IMMUCELL CORP /DE/ (ICCC) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, IMMUCELL CORP /DE/'s filing signal continuing positive.

ImmuCell Corporation is an animal health biologics company focused on developing, manufacturing, and commercializing products to improve the health and survivability of neonatal dairy and beef calves, primarily addressing calf scours. Its flagship product line, First Defense, utilizes hyperimmunized bovine colostrum to deliver pathogen-specific antibodies, providing 'Immediate ImmunityTM' against common causes of calf diarrhea. The company markets First Defense in various formats, including boluses, gels, and powders, through a network of animal health distributors. In December 2025, ImmuCell pivoted its strategy to concentrate solely on the First Defense franchise, pausing further investment in its Re-Tain mastitis treatment product and repurposing related assets for First Defense capacity expansion. The company aims to grow its market share through increased customer outreach, international expansion, product innovation, and manufacturing capacity enhancements.

Revenue is primarily driven by sales of the First Defense product line, which accounted for 99% of total product sales in 2025. Sales of the California Mastitis Test (CMT) represent the remaining 1%.